Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
14(70%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
3
15%
Ph phase_3
10
50%
Ph phase_1
7
35%

Phase Distribution

7

Early Stage

3

Mid Stage

10

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
7(35.0%)
Phase 2Efficacy & side effects
3(15.0%)
Phase 3Large-scale testing
10(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

14

trials recruiting

Total Trials

20

all time

Status Distribution
Active(15)
Completed(5)

Detailed Status

Active, not recruiting7
Recruiting7
Completed5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
14
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (35.0%)
Phase 23 (15.0%)
Phase 310 (50.0%)

Trials by Status

active_not_recruiting735%
completed525%
recruiting735%
not_yet_recruiting15%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT07313761Phase 1

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Completed
NCT07684235Phase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Recruiting
NCT07225686Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Recruiting
NCT07037433Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Recruiting
NCT07575399Phase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Recruiting
NCT07523711Phase 1

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Active Not Recruiting
NCT07684144Phase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Not Yet Recruiting
NCT07037459Phase 3

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Recruiting
NCT07441252Phase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Recruiting
NCT07226778Phase 1

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Completed
NCT07160257Phase 1

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

Active Not Recruiting
NCT07226765Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Recruiting
NCT07229157Phase 1

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Active Not Recruiting
NCT05669599Phase 2

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Completed
NCT06352892Phase 1

A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

Completed
NCT06858878Phase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Active Not Recruiting
NCT06987695Phase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Active Not Recruiting
NCT04478708Phase 1

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Completed
NCT06660173Phase 2

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Active Not Recruiting
NCT06858839Phase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Active Not Recruiting

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20